![Kimberly Freeman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kimberly Freeman
Corporate Officer/Principal chez ZENTALIS PHARMACEUTICALS, INC.
Provenance du réseau au premier degré de Kimberly Freeman
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 19 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Kimberly Freeman via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Lengo Therapeutics, Inc.
![]() Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Executive Officer Chairman | |
Kalyra Pharmaceuticals, Inc.
![]() Kalyra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kalyra Pharmaceuticals, Inc. manufactures small molecule drugs. The company was founded by Brian T. Dorsey, Cam L. Garner and Kevin Bunker and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Founder | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Chairman | |
CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Palleon Pharmaceuticals, Inc.
![]() Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Oncternal Oncology, Inc.
![]() Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Lilly Oncology
![]() Lilly Oncology Hospital/Nursing ManagementHealth Services Part of Eli Lilly & Co., Lilly Oncology is an American company dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. With over 50 years of experience, Lilly Oncology is committed to building on their heritage and improving the lives of all those affected by cancer worldwide. | Hospital/Nursing Management | Corporate Officer/Principal | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Duke Cancer Institute
![]() Duke Cancer Institute Hospital/Nursing ManagementHealth Services Duke Cancer Institute is an organization that unites the academic and clinical communities of Duke University and the Duke University Health System. The non-profit company is based in Durham, NC and has subsidiaries in the United States. The company's main focus is to provide access to technologies, services, and scientific consultation through its Shared Resources. | Hospital/Nursing Management | Corporate Officer/Principal | |
Goldman Sachs International
![]() Goldman Sachs International Investment Banks/BrokersFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Investment Banks/Brokers | Analyst-Equity | |
Mayo Clinic College of Medicine & Science | College/University | Doctorate Degree | |
Fore Biotherapeutics, Inc.
![]() Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member | |
CENTURY THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Cereius, Inc.
![]() Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Biotechnology | Founder | |
University of California San Diego | College/University | Doctorate Degree | |
Duke University
![]() Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree | |
Solve Therapeutics, Inc.
![]() Solve Therapeutics, Inc. BiotechnologyHealth Technology Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation. | Biotechnology | Founder | |
Tempus Labs, Inc.
![]() Tempus Labs, Inc. Packaged SoftwareTechnology Services Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL. | Packaged Software | Chief Tech/Sci/R&D Officer | |
IMAGO BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Tuck School of Business at Dartmouth | College/University | Masters Business Admin | |
Texas Southern University | College/University | Doctorate Degree | |
Leerink Partners LLC
![]() Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Investment Banks/Brokers | Analyst-Equity | |
CVS HEALTH CORPORATION | Drugstore Chains | Corporate Officer/Principal | |
H.I.G. BioHealth Partners LLC
![]() H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe. | Investment Managers | Private Equity Investor | |
UBS AG (New York)
![]() UBS AG (New York) Investment ManagersFinance UBS AG's (NYSE: UBS) New York City-based wealth management arm is known as UBS Private Banking (US). The firm provides a range of customized wealth management products and services for private clients. | Investment Managers | Corporate Officer/Principal | |
BIOCOM
![]() BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
SYNTHORX, INC. | Biotechnology | Corporate Officer/Principal | |
Endeavor BioMedicines, Inc
![]() Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Miscellaneous Commercial Services | President | |
Acerta Pharma BV
![]() Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Pharmaceuticals: Generic | Chief Executive Officer | |
Presage Biosciences, Inc.
![]() Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Chairman | |
Indiana University | College/University | Undergraduate Degree | |
Zentera Therapeutics (Shanghai) Co., Ltd.
![]() Zentera Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Zentera Therapeutics (Shanghai) Co., Ltd. is a biopharmaceutical company based in Shanghai, China. The Chinese company develops molecule therapeutics that target cancers. | Pharmaceuticals: Major | Director/Board Member | |
Arizona State University | College/University | Undergraduate Degree | |
CureVac SE
![]() CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Corporate Officer/Principal | |
IDEAYA BIOSCIENCES, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel | |
Southwestern University | College/University | Undergraduate Degree | |
Tulane University School of Medicine | College/University | Doctorate Degree | |
Tulane University School of Public Health & Tropical Medicine | College/University | Graduate Degree | |
TSCAN THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Kartos Therapeutics, Inc.
![]() Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Pharmaceuticals: Major | Chief Operating Officer | |
The University of California, San Francisco | College/University | Doctorate Degree | |
University of California, Berkeley | College/University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 44 |
Royaume-Uni | 3 |
Chine | 3 |
Pays-Bas | 2 |
Allemagne | 2 |
Sectorielle
Health Technology | 25 |
Consumer Services | 14 |
Commercial Services | 5 |
Finance | 5 |
Health Services | 3 |
Opérationnelle
Director/Board Member | 59 |
Corporate Officer/Principal | 36 |
Independent Dir/Board Member | 21 |
Chief Tech/Sci/R&D Officer | 16 |
Undergraduate Degree | 15 |
Relations les plus connectées
Insiders | |
---|---|
Cam Gallagher | 24 |
Kyle Rasbach | 15 |
Melissa Epperly | 13 |
Diana Hausman | 13 |
Enoch K. Kariuki | 13 |
Kimberly Blackwell | 13 |
Karan Takhar | 11 |
David Johnson | 11 |
Jan Skvarka | 10 |
Carrie Brownstein | 8 |
Andrea Paul | 8 |
Chrystal Louis | 7 |
Iris Roth | 6 |
Dimitris Voliotis | 5 |
Meena Rao | 5 |
- Bourse
- Insiders
- Kimberly Freeman
- Connexions Sociétés